Researchers at the University of Illinois Urbana-Champaign have reported a breakthrough in nickel catalysis that harnesses a ...

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

Moore’s widower, S. Robert Levine, MD, launched the nonprofit in his famous wife’s memory to advance research and accelerate ...

A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a ...

In a recent study, a team of scientists discovered that a treatment using different medications was found to be effective to ...

Several factors contribute to its high mortality. Early detection improves chances of survival but there is no effective ...

A new study from researchers in Spain discovered that triple therapy could entirely eliminate pancreatic cancer in mice.

A busy week of quarterly results delivered regulatory milestones, broker upgrades and mixed share-price moves across ASX healthcare.

Scientists hope their findings will potentially spare tens of thousands of future heart patients from undergoing a procedure.

Now, TriAgenics says it is approaching a critical milestone. The company is preparing to move through FDA review. This is the ...

Nine Medtech Startups Spanning AI Diagnostics, Surgical Robotics, Drug Delivery, and Orthopedic Implants Featured, Five ...

In December, the FDA granted breakthrough status for an implantable kidney replacement system for patients with end-stage kidney disease, according to a company press release.The Holly device by ...